EnteroBiotix Announces First Patient Dosed in Phase 2b RISE Study of EBX-102-02 in Irritable Bowel Syndrome with Constipation

Trial StartEBX-102-02Positive

AI Analysis

Summary

EnteroBiotix announced the first patient dosed in its Phase 2b RISE study of EBX-102-02 for moderate-to-severe irritable bowel syndrome with constipation. This marks a clinical development milestone for the orally delivered microbiome therapeutic candidate.

Clinical Trial Data

Phase

Phase 2b

Outcome Details

First patient dosed in Phase 2b RISE study

Importance:5/10

Sentiment:

0.60

microbiome therapeuticgastrointestinal diseaseIBS-Cclinical trialtrial initiation

Related Companies

$SPPI $TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on July 7, 2026 8:00 AM

Read Original